Progressive kidney damage in diabetes is one of the most significant risk factors for early disability and death. Chronic kidney disease (CKD) makes a significant contribution to the decreased quality of life of patients with diabetes mellitus (DM). The use of both general questionnaires (SF-36, SF-12 and EQ-5D) and numerous diabetes-specific ones reveals a pronounced decrease in the quality of life (QOL) of patients against the background of worsening CKD, in particular when reaching 3b–5 stages. The main pharmacological approaches recommended for the management of diabetic patients with CKD include such groups of drugs as renin-angiotensin-aldosterone system (RAAS) inhibitors, sodium-glucose cotransporter type 2 inhibitors (SGLT-2), as well as finerenone, a non-steroidal selective antagonist of mineralocorticoids. receptors. Studies of the dynamics of quality of life in diabetic patients with kidney pathology against the background of the use of RAAS inhibitors reveal its significant improvement in various patient populations. SGLT-2 inhibitors cause the most pronounced improvement in quality of life in patients with chronic heart failure, both with and without diabetes. Numerous clinical studies on the effectiveness of finerenone have demonstrated a significant improvement in renal function and a slowdown in the CKD progression, which can prevent patient disability, the onset of end-stage renal failure, concomitant limitations in physical functioning, psycho-emotional disorders, dependence on others and reduce the burden of the disease in general. These factors underlie the ability of finerenone to improve the quality of life of diabetic patients with CKD, having a positive effect on the duration of a full life.

Keywords: renin-angiotensin-aldosterone system inhibitors, selective nonsteroidal mineralocorticoid receptor antagonist, finerenone, sodium-glucose cotransporter type 2 inhibitors, diabetes mellitus, chronic kidney disease, quality of life